sudeng (HIPPO) fluctuates 40.9% in 24 hours: Active speculative trading drives sharp price swings
Bitget Pulse2026/04/07 00:28Volatility Overview
In the past 24 hours, HIPPO's price rebounded from a low of $0.000340 to a high of $0.000479, currently quoted at $0.000356, with an overall price fluctuation range of 40.9%. Trading volume surged by 30.8% to $6.51 million, with a turnover rate nearly 2.21 times its market cap, showing active high-frequency speculation.
Brief Analysis of Movement Reasons
- Speculative trading dominant: There were no official announcements or major news within 24 hours, and price volatility was mainly driven by high turnover and futures price momentum.
- On-chain data calm: No significant whale activity or large transfers detected.
Market Views and Outlook
Community sentiment is divided, with traders focusing more on short-term rebound opportunities (such as the $0.0004-$0.0005 range), but analysis from sources like Finora AI pointed out that if the $0.0004287 resistance is not reclaimed, downside risks remain, potentially targeting below $0.00034. Discussions on Platform X are mostly centered around technical signals, with caution regarding the potential delisting impact from Binance Futures.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
